

Financial Tear Sheet

Corporate Profile

Investors

BeyondSpring is a global, clinical-stage biopharmaceutical company focused on the development of innovative cancer therapies. Its lead asset, immuno-oncology agent Plinabulin, is currently in multiple global registration studies, for the prevention of chemotherapy-induced neutropenia and as an anticancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC). The Company also has a robust internal early-stage pipeline, and a research collaboration with Fred Hutchinson Cancer Research Center and University of Washington exploring the ubiquitin ligase protein to target and promote the destruction of disease causing proteins, such as oncogenes.

Led by a highly qualified management team with proven pharmaceutical experience and a combined 30+ drugs brought to market, and a unique, highly scalable business model that integrates clinical resources in the U.S. and China, BeyondSpring believes that it is well positioned for expeditious progress towards regulatory approvals and commercialization in a cost-efficient manner.

Primary IR Contact

Laura Perry / Joe Rayne

Argot Partners

Phone: 212.600.1902

E-mail:

BeyondSpring@argotpartners.com

Stock Information

BYSI (Common Stock)

Exchange NASDAQ CM (US Dollar)

Price **\$26.58**

Change (%) **▲ 0.78 (3.02%)**

Volume 1,686


52 Week Low \$19.55

Market Cap \$579,332,410

Rolling EPS -2.70

PE Ratio 0

Shares Outstanding 22,455,702



Recent Press Releases & Upcoming Events

June 25, 2018

[BeyondSpring's Principal Investigator in China for Chemotherapy-Induced Neutropenia Delivered Keynote Presentation at 12th Annual Chinese Symposium on Medical Oncology and 7th Annual Meeting of the Chinese Association for Clinical Oncologists](#)

June 21, 2018

[BeyondSpring Provides Operational Updates and First-Quarter 2018 Financial Results](#)

June 18, 2018

[BeyondSpring to Host First-Quarter 2018 Financial Results Conference Call on June 21, 2018](#)

There are currently no events scheduled.

SEC Filings

Filing Date	Form
June 21, 2018	<u>6-K</u>
May 30, 2018	<u>6-K</u>
May 29, 2018	<u>424B5</u>
May 16, 2018	<u>20-F/A</u>

Corporate Governance

<u>Lan Huang, Ph.D.</u>	Co-founder, Chairman & CEO
<u>Ramon Mohanlal, M.D., Ph.D.</u>	Chief Medical Officer
<u>Edward Dongheng Liu</u>	Chief Financial Officer
<u>G. Kenneth Lloyd, Ph.D.</u>	Chief Scientific Officer
<u>Gordon L. Schooley, Ph.D.</u>	Chief Regulatory Officer